Blueprint Medicines Corporation (BPMC) News
Filter BPMC News Items
BPMC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BPMC News Highlights
- BPMC's 30 day story count now stands at 10.
- Over the past 12 days, the trend for BPMC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BPMC are ASH, AXSM and GILD.
Latest BPMC News From Around the Web
Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PT (1:30 p.m. ET). |
Blueprint Medicines Corporation's (NASDAQ:BPMC) 38% Price Boost Is Out Of Tune With RevenuesBlueprint Medicines Corporation ( NASDAQ:BPMC ) shares have continued their recent momentum with a 38% gain in the last... |
Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)Blueprint Medicines Corp (NASDAQ:BPMC) has recently witnessed a notable insider sell by Director Jeffrey Albers, who disposed of 5,000 shares of the company's stock. |
Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. |
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisBlueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe. |
Blueprint Medicines' (NASDAQ:BPMC) investors will be pleased with their respectable 63% return over the last yearThe simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by... |
12 Best Genomics Stocks To Buy NowIn this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […] |
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingBlueprint Medicines Corporation (Nasdaq: BPMC) today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12 in San Diego. Data that will be presented include results from the HARBOR Part 1 trial of elenestinib in indolent systemic mastocytosis (ISM) and analyses of real-world data highlighting the burden of and urgency to tr |
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |